PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

Acute Coronary Syndrome (ACS) - Global Drug Forecast and Market Analysis to 2025 the report provides Overview of Acute Coronary Syndrome (ACUTE CORONARY SYNDROME (ACS), including the main driver of the significant expansion of the ACUTE CORONARY SYNDROME (ACS) market will be the increase in use and physician confidence in the PCSK9 inhibitor class, which will hold four major players by the end of this forecast. Novel lipid lowering therapy, ETC-1002, will also be a major contributor, vying to steal majority of patient shares for the statin intolerant ACUTE CORONARY SYNDROME (ACS) population by the end of this forecast. The major global barrier for the ACUTE CORONARY SYNDROME (ACS) market will be the generic erosion of the key antiplatelet therapies, Brilinta and Effient by the end of this forecast. Both drugs will pick up significant momentum in sales prior to patent expiry.

Complete report on Acute Coronary Syndrome (ACS) - Global Drug Forecast and Market Analysis to 2025 with 155 tables and 26 Figures Spread across 416 pages is available at http://www.reportsnreports.com/contacts/discount.aspx?name=745054

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Major Points Covered in Table of Contents

·         Epidemiological Forecast for Acute Coronary Syndrome (ACS) (2015-2025).

·         Global Acute Coronary Syndrome (ACS) Sales Forecast ($M) 2015-2025.

·         Diagnosis and Treatment Overview for Acute Coronary Syndrome (ACS).

·         Product Profiles - Acute Coronary Syndrome (ACS).

·         Promising Drugs in Clinical Development for Acute Coronary Syndrome (ACS).

·         Current and Future Players.

·         Global Market Outlook for Acute Coronary Syndrome (ACS).

Request Report Sample at http://www.reportsnreports.com/contacts/requestsample.aspx?name=745054

Companies Discussed In This Report:

Amgen, AstraZeneca, Bristol-Myers Squibb, Cerenis Therapeutics, CSL Limited, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, Janssen, Merck & Co, Pfizer, Sanofi 

Drug Profile Discussed In This Report:

Bococizumab , Anacetrapib , CSL-112, CER-001, LY3015014, AMG-899 ETC-1002

Scope

·         Overview of ACUTE CORONARY SYNDROME (ACS), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

·         Annualized ACUTE CORONARY SYNDROME (ACS) therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.

·         Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ACUTE CORONARY SYNDROME (ACS) therapeutics market.

·         Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

·         Analysis of the current and future market competition in the global ACUTE CORONARY SYNDROME (ACS) therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Purchase a Copy of Report at: http://www.reportsnreports.com/purchase.aspx?name=745054. OR Get a DISCOUNT at http://www.reportsnreports.com/contacts/discount.aspx?name=745054.

Reasons to buy:

The report will enable you to -

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. Develop business strategies by understanding the trends shaping and driving the global ACUTE CORONARY SYNDROME (ACS) therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ACUTE CORONARY SYNDROME (ACS) therapeutics market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Track drug sales in the global ACUTE CORONARY SYNDROME (ACS) therapeutics market from 2015-2025.Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Explore Other Reports on Pharmaceuticals Market at http://www.reportsnreports.com/market-research/pharmaceuticals/.

About Us:

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.